Pharmaceutical Price Wars: $129K-A-Year Cancer Drug Next In The Cross Hairs
Lawmakers are urging federal agencies to step in to cut prices of Xtandi, a prostate cancer drug that's price is four times more expensive in the United States than in other developed countries.
The Associated Press:
Another Drug Company In The Crosshairs Of Congress
Another pharmaceutical company is being targeted by lawmakers over drug pricing. Shares of Medivation tumbled more than 6% in premarket trading Tuesday after a group of lawmakers opened a campaign to potentially lower the price of its prostate cancer drug. They are asking for public hearings over the drug, which they say was developed at the University of California, Los Angeles, through taxpayer-supported research grants. It is sold by Japanese drug maker Astellas Pharma. (3/29)